Trial Profile
Phase 1 study of Selective Orexin 1 Receptor Antagonist (ACT 335827) in patients with neurological disorders
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Nov 2016
Price :
$35
*
At a glance
- Drugs ACT 335827 (Primary)
- Indications Neurological disorders
- Focus Adverse reactions
- 18 Nov 2016 New trial record